Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PF3F | ISIN: US70465T1079 | Ticker-Symbol: EU6
Tradegate
05.06.25 | 11:07
1,393 Euro
-3,93 % -0,057
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PDS BIOTECHNOLOGY CORPORATION Chart 1 Jahr
5-Tage-Chart
PDS BIOTECHNOLOGY CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
1,4021,45211:52
1,3861,43911:52

Aktuelle News zur PDS BIOTECHNOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoPDS Biotech reports steady survival rates in HPV16-positive HNSCC trial2
MoPDS Biotechnology Corporation: PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology ...110Median overall survival data in first-line recurrent/metastatic (1L r/m) HNSCC remains durable at 30.0 months with additional follow-up of ~4.5 months beyond the initial abstract HPV16-positive is...
► Artikel lesen
MoPDS Biotechnology Corp - 8-K, Current Report1
27.05.PDS Biotechnology files to sell 9.82M shares of common stock for holders5
23.05.PDS Biotechnology Corporation (PDSB)'s Versamune HPV Surpasses Survival Benchmarks in Recurrent Head and Neck Cancer Trial4
22.05.PDS Biotech reports extended survival in HPV cancer study7
22.05.PDS Biotechnology Corporation: PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) ...86Phase 2: Versamune® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC - Median overall survival for CPS =20 is 39.3 months - Median overall survival for CPS =1 is 30.0 months...
► Artikel lesen
22.05.PDS Biotechnology Corp - 8-K, Current Report1
PDS BIOTECHNOLOGY Aktie jetzt für 0€ handeln
20.05.PDS Biotechnology Corporation: PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase4
14.05.PDS Biotechnology Corp - 10-Q, Quarterly Report2
14.05.PDS Biotech treibt Phase-3-Studie voran und veröffentlicht Finanzergebnisse für Q15
14.05.PDS Biotech advances Phase 3 trial, reports Q1 financials1
14.05.PDS Biotechnology Corporation: PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update118 VERSATILE-003 Phase 3 Site Initiations Underway Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00...
► Artikel lesen
14.05.PDS Biotechnology GAAP EPS of -$0.21 beats by $0.041
14.05.PDS Biotechnology Corp - 8-K, Current Report1
13.05.Insights Ahead: PDS Biotechnology's Quarterly Earnings1
09.05.PDS Biotechnology Corporation: PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)131PRINCETON, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the...
► Artikel lesen
02.05.PDS Biotechnology Corp - 8-K, Current Report17
24.04.PDS Biotechnology Corp - 8-K, Current Report8
23.04.PDS Biotechnology Corporation: PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting2
Seite:  Weiter >>
48 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1